

CURRICULUM VITAE

Ghazaleh Bahrami, MD

EDUCATION

- 2011** **Medical College of Wisconsin**
Milwaukee, Wisconsin
Department of Medicine, Internal Medicine
- 2007** **Ross University School of Medicine**
Miramar, FL
Doctor of Medicine, Cum Laude
- 2003** **University of Texas at San Antonio (UTSA)**
San Antonio, TX
Bachelor of Science in Biology, Cum Laude
- 2001** **University of Texas at Austin**
Austin, TX
Doctor of Pharmacy, Incomplete

Licenses

	Licensure Number	Issue Date	Expiration
Internal medicine board certified	320131	11/2011	12/31/2029
California	A117471	07/1/2011	01/31/2028
DEA	FB2635401	07/31/2017	07/31/2026
MI	4301506611	03/01/2022	03/30/2028
IMLC (22 active licenses)		03/01/2025	03/30/2028

Certifications

Advanced Cardiac Life Support (ACLS) and BLS

03/02/2025

03/02/2027

Anti-aging medicine certification obtained from Empire medical training (2016)

Advanced physician Medical Monitor Certification (APMMC) obtained from CCRPS (2022)

Design and Interpretation of Clinical Trials obtained from Johns Hopkins university online course (2020)

CLINICAL RESEARCH

2008 -2009 National Institutes of Health (NIH) Bethesda, MD

-Anti-inflammatory effect of Statin (Lipitor) in patients with Sarcoidosis, Control Randomized Clinical Trial, Double Blinded Placebo

-Meta-analysis review of treatment studies in pulmonary Sarcoidosis

-Comparison of inflammatory biomarkers and steroid use in Sarcoidosis patients previously treated with pentoxifylline, Statin and placebo, Retrospective study.

-Study of inflammatory and Hemostatic biomarkers in Sarcoidosis patients, Retrospective study.

2020-now Synexus clinical research (Trialmed is the new unified brand name replacing Synexus, PPD, Optimal and Radiant)

Cerritos, CA

PROFESSIONAL PRESENTATIONS

2009 Society of General Internal Medicine Annual Meeting

Chicago, IL

- Mycoplasma Pneumoniae causing mucosal limited Stevens Johnsons syndrome (case presentation)

2011 International Association for Study of Lung Cancer

Amsterdam, Netherlands

- Prevalence of oligometastatic in non-small cell lung cancer and Pattern of failure analysis after first line chemotherapy, the role of consolidation chemotherapy (oral and poster presentation)

2016 National Heart, Lung, and Blood Institute (NHLBI)

Bethesda, MD

- Atorvastatin Treatment for pulmonary Sarcoidosis, a Randomized, Double-Blind,

Placebo-controlled Clinical Trial (publication)

Professional Experiences

2020- Present Principal Investigator

Trialmed (new unified brand for the previous Synexus, PPD, AES, optimal and Radiant))

Cerritos, CA

Conduct studies in compliance with protocols and Good clinical Practice (GCP) and ensure all persons assisting me in the study are adequately trained and supervised in the delegated trials duties, making sure all assessments and procedures are followed per specific study protocols, following the pharmacovigilance and safety assessments of all subjects enrolled in the study, and detecting AE and SAE/MAAE and follow all regulatory reporting requirements. knowledge of relevant Food and Drug Administration (FDA) and International Conference on Harmonization (ICH) guidelines, initiatives, and regulations governing drug safety reporting of clinical trials.

- Pulmonary: Anti-inflammatory Effect of Statin in Patients with Sarcoidosis. Controlled Randomized Clinical Trial Double Blind Placebo.
 - Gastroenterology: Prevention of colorectal cancer through XXX testing, a multicenter validation study.
 - Gastroenterology: A prospective, observational multicenter study without randomization, to evaluate sensitivity and specificity of a blood-based XXX test to detect colorectal cancer in a screen-relevant, average risk population.
 - Pulmonary: Meta-Analysis Review of Treatment Studies in Pulmonary Sarcoidosis
 - Pulmonary: Retrospective Study Comparison of Inflammatory Biomarkers and the Steroid Use in Sarcoidosis Patients Previously Treated with XXX, Statin and Placebo.
 - Pulmonary: Phase 2 Double Blinded Randomized placebo-controlled study of efficacy and safety of multiple Dose XX orally in 12 weeks in adults with moderate-severe uncontrolled Asthma.
 - Pulmonary: Four weeks Randomized double blinded placebo-controlled study safety and efficacy of parallel group combined Albuterol+ fluticasone or albuterol, Fluticasone, or placebo derived by multidose powder inhaler in participant older than 12 years old with Asthma
 - Pulmonary: Retrospective Study of Inflammatory and Hemostatic Biomarkers in Sarcoidosis Patients.
- Oncology: Prevalence of Oligometastatic in Non-Small Cell Lung Cancer and Pattern of Failure Analysis after First Line Chemotherapy, the Role of Consolidation Chemotherapy.
 - Pulmonary: Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of XXX 100mg Sc as Add on Treatment in Participants with COPD Characterized by Frequent Exacerbations and Eosinophil Level

- Infectious Disease: Phase III, Randomized, Double-Blinded, Placebo-Controlled Phase 3 Study to Access Efficacy and Safety of XXX For Prevention of Sar-Cov-2-Mediated Covid-19 in adults aged 18 and older.
- Infectious Disease: Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study in Adults to Determine the Safety and Efficacy Of XXX, A Combination Product of Two Monoclonal Antibodies for Pre-Exposure Prophylaxis Of COVID-19
- Infectious Disease: Phase III, Randomized, Double-blind placebo-controlled efficacy study of an XXXXXXXXXXXX vaccine in the prevention of lower respiratory tract disease caused by RSV in adults aged 60 years and older.
- Infectious Disease: Phase III, Randomized, Double-blind placebo-controlled Efficacy study of xxxx vaccine in prevention of seasonal Flu in adults aged greater than 18 years old.
- Infectious Disease: A Phase 3, Randomized, Observer-blind, Active-control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of (xxx) Vaccine in Healthy Adult Participants, ≥50 Years of Age
- Infectious Disease: Phase I/II, Randomized, Stratified, observer-blind study to evaluate safety and reactogenicity, and immunogenicity of vaccine xxx in SAR-Cov2 and Flu compared to mRNA vaccine for Flu and mRNA vaccine in SAR-Cov2 in adults 18 to 75 years old
- Infectious Disease : A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of xx-049 (follow- up of xx-006/022 studies) to assess the prophylactic efficacy, safety and persistence of immune response of a Herpes Zoster subunit vaccine and assessment of persistence of immune response and safety of 1 or 2 additional doses administered in 2 subgroups of older adults.
- Infectious Disease: An open Label Phase 3b, to evaluate antibody persistence and long-term safety of live- CHIKUNGUNYA virus Vaccine in adults 18 years and older
- Cardiovascular: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of xxx on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants with Body Mass Index ≥27 kg/m² and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease.
- Cardiovascular: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of xxx on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a).
- Cardiovascular: open label study to assess long term safety and efficacy and tolerability of XXX in subjects with hypertension
- Obesity: Phase 2 double blinded placebo-controlled study of safety and efficacy of oral daily XXX in obese subjects with comorbidities
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of xx Tablets in Overweight/Obese Participant

- Neuroscience: Phase IB Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to determine Efficacy, Pharmacokinetics and Safety of XXX-XXX in Agitation associated with Schizophrenia
- Neuroscience: Phase IIIB Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects with Schizophrenia Treated Prospectively for 6-months with XXX-XXX (OTSIQVSCZ301, 031- 201003010)
- Neuroscience: Phase III, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with XXX-XXX in Adult Subjects with Major Depressive Disorder (SAGSYHMDD303, 217-MDD-303)
- Infectious Disease: Phase III, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of XXXX seasonal Influenza vaccine in adults 18 years and older.
- Infectious Disease: Phase III, Randomized, Placebo- Controlled, Observer-Blind, Multi- Country Study to Demonstrate the Efficacy of a Single Dose XXX-XXX Investigational Vaccine against RSV in Adults Aged 60 And Above
- Infectious Disease: phase III, Randomized-Blinded Study to evaluate the safety, Tolerability and immunogenicity of a combined modified RNA Vaccine against Covid-19 and Influenza in healthy individuals.
- Infectious Disease: phase I/II parallel, randomized, modified double-blind, multi arm study to assess the safety and immunogenicity of a combination vaccine of different recombinant spike antigen levels of a matrix-m adjuvant and recombinant Covid-19 vaccine and recombinant Influenza vaccine in adults 50 years and older
- Neuroscience: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXX as an Adjunctive Treatment in Adult Patients with Schizophrenia (CONXXXSCZ001, CTP692.2001)
- Neuroscience: A Phase III Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of XXX in Subjects with Schizophrenia (SUNIQVSCZ304, SEP361304)
- Neuroscience: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XX as Adjunctive Treatment in Subjects with Schizophrenia
- Neuroscience: A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive XX in Subjects with Inadequately Controlled Symptoms of Schizophrenia
- Neuroscience: An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive XX in Subjects with Inadequately Controlled Symptoms of Schizophrenia
- Neuroscience: A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study to determine efficacy and safety and safety of XX in agitation associated with bipolar disorder

2021-2023 Telemedicine Physician

Wellnite Health

Evaluate and treat depression, anxiety and bipolar.

2020-2025 Telemedicine Physician

SteadyMD

Covid 19 evaluation and treatments, general med

2019-2020 Assisted living/Nursing home.

House-call MD, Beverly Hills, CA

Primary physician for multiple assisted living facilities, arranging home visits, Hospice care, competency assessments, using tele-consult during covid19 pandemic mitigation.

2018 – 2019 Hospitalist/Internist (Arya Group)

St. Agnes Hospital, Fresno, CA

Fresno Surgical Hospital, Fresno, CA

Madera Community Hospital, Fresno,

General hospitalist work, open ICU responding to code blue, attending daily case management rounds and utilization reviews for safe discharge, placement to rehab or nursing home facilities.

2016-2019 Hospitalist/Internist (VEP Group)

Martin Luther King Community Hospital, Compton, CA

General hospitalist work includes managing day-to-day care and providing prompt and complete attention to all patient care needs including diagnosis, treatment, and the performance of medical procedures in underprivileged inner-city neighborhoods with extreme socioeconomic challenges, and complicated medical and social history.

2014 -2015 Hospitalist/Internist (RPG Group)

Fairchild medical center, Yreka, CA

Colusa medical center, Colusa, CA

Hospitalists in rural areas considered critical access hospitals, limited specialist, open ICU without intensivists backup, besides general hospitalist work given rural nature of facilities and lack of other available care, I was managing patients in ER and ICU including ventilated patients, many times stabilizing very sick patients before transferring to higher level of care.

2015-2016 Teaching attending (family medicine residency)

Downey medical center, Downey, CA

Participating in daily teaching rounds and supervising residents, interns, and medical students

2013-2014 Hospitalist/Internist (CareMore Medicare advantage Group)

Presbyterians Inter-community hospital, Whittier, CA

General hospitalists work with geriatrics populations and maintain a continuity of care in outpatient focusing on preventive care and follow ups with goal of minimizing ER visits and hospital bed days.

2012-2013 Urgent care /primary care

Kaiser Permanente Woodland Hills, CA

Responsible for providing outpatient and urgent medical care in San Fernando Valley

2011– 2012 Hospitalist/Internist (AppleCare Medical Group)

Downey Regional Medical Center, Downey, CA

St Francis Medical Center, Lynwood, CA

Lakewood Medical Center, Lakewood, CA

General hospitalist/Internist work, open ICU

HONORS AND AWARDS

2007-2008 Post-Doctoral Research Fellow IRTA award

2001-2003 Premed Honor Society

1999-2003 Phi Theta Kappa Honor Society

PROFESSIONAL SOCIETIES AND ORGANIZATIONS

2008 Member, American College of Physicians

2008 Present Member, American Medical Association

LANGUAGES

Farsi

English

COMPUTER PROFICIENCY

- CERNER
- EPIC
- Meditech

- Microsoft Word, PowerPoint, Excel
- EDC, Medidata, Signet

THERAPUTIC EXPERINCE AND EXPERTIES

- COPD, Asthma
- COVID-19, Flu, RSV, chikungunya
- Diabetes, Hypertension, hyperlipidemia
- Major Depressive Disorder, Bipolar disorder
- Obesity
- Autoimmune disorders
- Vaccine
- Cardiovascular

SCALES AND PATIENT REPORTED OUTCOME MEASURE EXPERINCE

- Columbia-suicide Severity Scale (C-SSRS)
- Mini-Mental Status Examination (MMSE)
- Physician's Global Assessment
- Health-Related Quality of Life (HR-QoL)
- Short Form Survey (SF-12)
- Patient Health Question (PHQ-8)
- Montreal Cognitive Assessment (MOCA)